SG11201705727TA - 9h-pyrrolo-dipyridine derivatives - Google Patents

9h-pyrrolo-dipyridine derivatives

Info

Publication number
SG11201705727TA
SG11201705727TA SG11201705727TA SG11201705727TA SG11201705727TA SG 11201705727T A SG11201705727T A SG 11201705727TA SG 11201705727T A SG11201705727T A SG 11201705727TA SG 11201705727T A SG11201705727T A SG 11201705727TA SG 11201705727T A SG11201705727T A SG 11201705727TA
Authority
SG
Singapore
Prior art keywords
pyrrolo
dipyridine
derivatives
dipyridine derivatives
Prior art date
Application number
SG11201705727TA
Other languages
English (en)
Inventor
Joël Mercier
Laurent Provins
Celine Vermeiren
Yogesh Anil Sabnis
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of SG11201705727TA publication Critical patent/SG11201705727TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201705727TA 2015-02-02 2016-01-29 9h-pyrrolo-dipyridine derivatives SG11201705727TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15153448 2015-02-02
PCT/EP2016/051993 WO2016124508A1 (en) 2015-02-02 2016-01-29 9h-pyrrolo-dipyridine derivatives

Publications (1)

Publication Number Publication Date
SG11201705727TA true SG11201705727TA (en) 2017-08-30

Family

ID=52477553

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201705727TA SG11201705727TA (en) 2015-02-02 2016-01-29 9h-pyrrolo-dipyridine derivatives

Country Status (17)

Country Link
US (3) US20180022748A1 (es)
EP (1) EP3253762B1 (es)
JP (1) JP6579670B2 (es)
KR (1) KR102621513B1 (es)
CN (1) CN107207508B (es)
AU (1) AU2016214537B2 (es)
BR (1) BR112017016311A2 (es)
CA (1) CA2973648C (es)
CL (1) CL2017001923A1 (es)
DK (1) DK3253762T3 (es)
EA (1) EA036518B1 (es)
ES (1) ES2875734T3 (es)
IL (1) IL253381B (es)
MX (1) MX2017009505A (es)
MY (1) MY191590A (es)
SG (1) SG11201705727TA (es)
WO (1) WO2016124508A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2247558T4 (da) 2008-02-14 2024-07-29 Lilly Co Eli Nye billeddannelsesmidler til detektering af neurologisk dysfunktion
DK3253762T3 (da) * 2015-02-02 2021-07-19 UCB Biopharma SRL 9h-pyrrolo-dipyridinderivater.
EP3487545A1 (en) 2016-07-22 2019-05-29 AC Immune S.A. Compounds for imaging tau protein aggregates
CN109475648B (zh) * 2016-07-22 2023-03-14 Ac免疫有限公司 用于成像tau蛋白聚集体的化合物
SI3510031T1 (sl) * 2016-09-09 2021-03-31 F. Hoffmann-La Roche Ag Postopek za pripravo 2-(6-nitropiridin-3-il)-9H-dipirido(2,3-b;3',4'-d)pirola
CA3042260C (en) * 2016-11-01 2023-10-03 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
CA3067455C (en) 2017-06-02 2021-11-23 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating spinocerebellar ataxia
SG11201911520UA (en) * 2017-06-02 2020-01-30 Fujifilm Toyama Chemical Co Ltd Agent for preventing or treating tauopathy
CN116473962A (zh) 2017-06-02 2023-07-25 富士胶片富山化学株式会社 脑萎缩预防或治疗剂
WO2018221728A1 (ja) 2017-06-02 2018-12-06 富山化学工業株式会社 アルツハイマー型認知症予防または治療剤
KR20200003102A (ko) 2017-06-02 2020-01-08 후지필름 도야마 케미컬 가부시키가이샤 아밀로이드 β 단백질량 감소제
WO2019088083A1 (ja) 2017-10-30 2019-05-09 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用
WO2019145292A1 (en) * 2018-01-24 2019-08-01 Ac Immune Sa Azacarboline compounds for the detection of tau aggregates
WO2019145291A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Gamma-carboline compounds for the detection of tau aggregates
EP3743427B1 (en) * 2018-01-24 2022-10-19 AC Immune SA Novel method of preparing an imaging compound
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268771A (en) 1968-03-15 1972-03-29 Glaxo Lab Ltd Azacarbazoles
WO2008132454A1 (en) * 2007-04-26 2008-11-06 Ge Healthcare Limited Carbolines and their use as imaging agents
DK2247558T4 (da) * 2008-02-14 2024-07-29 Lilly Co Eli Nye billeddannelsesmidler til detektering af neurologisk dysfunktion
ES2490867T3 (es) * 2008-12-19 2014-09-04 Bristol-Myers Squibb Company Inhibidores de carbazol y carbolina quinasas
ES2792830T3 (es) * 2012-05-22 2020-11-12 Lilly Co Eli Agentes para formación de imagen en base a carbolina y carbazol, para la detección de disfunción neurológica
US20160115162A1 (en) * 2013-05-31 2016-04-28 The General Hospital Corporation Radiosynthesis of Tau Radiopharmaceuticals
CN105379130B (zh) * 2013-07-24 2017-08-22 瑞典爱立信有限公司 与无线电信号的接收有关的方法和设备
WO2015052105A1 (en) * 2013-10-08 2015-04-16 F. Hoffmann-La Roche Ag Diazacarbazole derivatives as tau-pet-ligands
US10662193B2 (en) * 2014-01-21 2020-05-26 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
DK3253762T3 (da) * 2015-02-02 2021-07-19 UCB Biopharma SRL 9h-pyrrolo-dipyridinderivater.

Also Published As

Publication number Publication date
EA201791733A1 (ru) 2018-01-31
US20220213103A1 (en) 2022-07-07
US11312716B2 (en) 2022-04-26
AU2016214537A1 (en) 2017-08-03
US12006316B2 (en) 2024-06-11
CL2017001923A1 (es) 2018-02-16
JP6579670B2 (ja) 2019-09-25
EA036518B1 (ru) 2020-11-18
ES2875734T3 (es) 2021-11-11
WO2016124508A1 (en) 2016-08-11
BR112017016311A2 (pt) 2018-03-27
US20210047326A1 (en) 2021-02-18
EP3253762A1 (en) 2017-12-13
US20180022748A1 (en) 2018-01-25
CN107207508A (zh) 2017-09-26
KR20170113607A (ko) 2017-10-12
CA2973648A1 (en) 2016-08-11
IL253381A0 (en) 2017-09-28
JP2018503673A (ja) 2018-02-08
MY191590A (en) 2022-06-30
EP3253762B1 (en) 2021-05-05
AU2016214537B2 (en) 2018-05-10
IL253381B (en) 2020-10-29
DK3253762T3 (da) 2021-07-19
CN107207508B (zh) 2020-02-28
KR102621513B1 (ko) 2024-01-04
CA2973648C (en) 2023-09-26
MX2017009505A (es) 2017-11-02

Similar Documents

Publication Publication Date Title
HK1255045A1 (zh) 取代的氧代吡啶衍生物
IL253311A0 (en) Green indoor cultivation
DK3256579T3 (en) Cysteinprotease
IL253381B (en) History of h9–pyrrolo–dipyridine
GB201506824D0 (en) TrailReach Multitrial
HK1245258A1 (zh) 新的二氟酮酰胺衍生物
GB201500806D0 (en) Aerosol-gnerating aticle
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
HUE050450T2 (hu) Fluoralkil-fluorén-származékok
IL248773A0 (en) History of naphthyridinedione
PL3418273T3 (pl) Pochodne flawaglin
GB201511039D0 (en) In-vitro-analyser
IL248629A0 (en) Substances containing diheteroaryl conjugated to cycloalkyl and their uses
AU361999S (en) Ballustrade
IL251005B (en) Pyrido-oxazinone derivatives
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
HK1259107A1 (zh) 氨基唑衍生物
PT3319956T (pt) Derivados de oxopiridina substituída
LT3365601T (lt) Krematoriumai
AU362754S (en) Playsuit
GB201504231D0 (en) SmartSneakers
GB201503997D0 (en) Mykee
GB201503535D0 (en) Drydam
GB201502069D0 (en) Drydam